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Abstract:  Traumatic brain injury (TBI) is the leading cause of death and disability 
for people under the age of 45 years worldwide. Neuropathology after TBI is the 
result of both the immediate impact injury and secondary injury mechanisms. 
Secondary injury is the result of cascade events, including glutamate excitotoxicity, 
calcium overloading, free radical generation and neuroinflammation, ultimately 
leading to brain cell death. In this study, the P2X7 receptor (P2X7R) was detected 
predominately in microglia of the cerebral cortex and were up-regulated on microglial 
cells after TBI. The microglia transformed into amoeba-like and discharged many 
microvesicle (MV)-like particles in the injured and adjacent regions. A P2X7R 
antagonist (A804598) and an immune inhibitor (FTY720) reduced significantly the 
number of MV-like particles in the injured/adjacent regions and in cerebrospinal fluid, 
reduced the number of neurons undergoing apoptotic cell death and increased the 
survival of neurons in the cerebral cortex injured and adjacent regions. Blockade of 
the P2X7R and FTY720 reduced interleukin-1βexpression, P38 phosphorylation and 
glial activation in the cerebral cortex, and improved neurobehavioral outcomes after 
TBI. These data indicate that MV-like particles discharged by microglia after TBI may 
be involved in the development of local inflammation and secondary nerve cells 
injury.   
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Introduction 
Traumatic brain injury (TBI) is the leading cause of death and disability for 
people under the age of 45 years [1]. Worldwide, about 10 million people are annually 
admitted to hospital after TBI. An estimated 57 million people have survived brain 
injury [2]. Neuropathology after TBI is the result of both the immediate impact injury 
and secondary injury mechanisms [3]. The immediate impact injury occurs at the time 
of exposure to the external force [4,5]. Secondary injury occurs from minutes to 
months after TBI and is the result of cascade events that ultimately lead to brain cell 
death, tissue damage and atrophy [6]. These cascade events include glutamate 
excitotoxicity, perturbation of cellular calcium homeostasis, increased free radical 
generation and lipid peroxidation, mitochondrial dysfunction, neuroinflammation [7]. 
The relative contributions of these different cascade events to the secondary injury 
remain to be determined. In addition to the excitatory amino acid glutamate, 
extracellular ATP acts as an important signal molecule in the processes of central 
nervous system (CNS) injury and is currently attracting more attention [8, 9, 10, 11,  
12]. There is a high concentration of extracellular ATP at the injured and adjacent 
regions of TBI that may be involved in the secondary injury after TBI. There is 
currently no information available about this.  
Microvesicles (MV) are small (0.1–1μm) vesicles which bud directly from the 
plasma membrane of many brain cell types and are released into the extracellular 
environment and regulate the functional activity of other cells. This is a novel method 
of cell-to-cell communication [13,14]. Previous data showed that ATP can trigger MV 
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shedding and interleukin (IL)-1β release from both microglia and astrocytes in vitro 
through a pathway which involves the P2X7 receptor (P2X7R), p38 MAPK cascade 
and lysosomal acid sphingomyelinase (A-SMase) [15]. As such, P2X7R antagonists 
and inhibitors of p38 MAPK and A-SMase can regulate MV shedding and IL-1β 
release from glial cells. FTY720 (Gilenya), an immunomodulator drug marketed as 
the first oral sphingosine-1-phosphate receptor modulator for treatment of multiple 
sclerosis, also inhibits lysosomal A-SMase [16]. 
The aim of this study was to study the roles of extracellular ATP via the P2X7R 
-p38 MAPK-A-SMase pathway in secondary injury after TBI. In this study, P2X7R 
was detected predominately in microglia of the cerebral cortex. After TBI, the 
microglia transformed into the amoeba-like form, shedding many MV-like particles at 
the injured and adjacent regions. The P2X7R antagonist, A804598, and FTY720 
reduced significantly the number of MV-like particles in the injured/adjacent regions 
and in cerebrospinal fluid (CSF) and improved the outcomes of TBI. These data 
indicate that MV-like particles discharged by microglia after TBI, may be involved in 
the development of local inflammation and secondary nerve cells injury.  
 
Material and Methods 
Animals and surgical procedures 
Male Sprague–Dawley rats weighing 250–300 g were provided by the Animal 
Center of Second Military Medical University. All experimental procedures were 
approved by the Institutional Animal Care and Use Committee at Second Military 
Medical University and conformed to the UK Animals (Scientiﬁc Procedures) Act 
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1986 and associated guidelines on the ethical use of animals.  
Rat TBI model 
The rats were anesthetized by an intraperitoneal injection of 10% Chloral hydrate, 
0.3ml/100g. A rectal probe was inserted and the animals were positioned on a 
thermistor controlled heating pad. All surgery was done under sterile conditions. The 
rats were randomly allocated into four groups as follows; a control (sham-operated) 
group, a TBI group, a group of TBI treated with A804598 and a group of TBI treated 
with FTY720, each group having 40 rats. The control group underwent craniotomy 
alone and received no medication. The TBI group underwent craniotomy followed by 
brain injury and received a physiological saline injection. The TBI group treated with 
A804598 underwent craniotomy followed by brain injury and then received A804598. 
The group of TBI treated with FTY720 underwent craniotomy followed by brain 
injury and then received FTY720 injection.  
For the production of brain injury, a modified weight drop technique was used 
according to the protocol of Feeney’s [17]. A craniotomy (6×6 mm2), centered over 
the right parietal cortex at bregma －3.5 and 3.5 mm lateral to the midline, was done 
using a dental drill. A 20 g weight was dropped from a height of 20 cm onto 4.5 mm 
diameter piston resting on the exposed dura. The device was constructed to prevent 
bouncing of the weight thus allowing only a single compression.  
The P2X7R antagonist A804598 (Tocris) and FTY720 (Santa Cruz) were 
prepared freshly by dissolving in 0.9% physiological saline and were administered 
intraperitoneally immediately after trauma. The dosages of A804598 and FTY720 
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were 10mg/kg and 0.2mg/kg respectively, once daily for the continuous five days. 
Immunohistochemistry  
The rats were anesthetized and perfused intracardially with saline, followed by 
4% (w/v) paraformaldehyde in 0.1 mol/L PBS, pH7.4. Brains were removed and fixed 
overnight in 4% (w/v) paraformaldehyde, then transferred to 25% sucrose in 
phosphate-buffered saline (PBS) and kept in the solution until they sank to the bottom. 
Thereafter, the tissue blocks were rapidly frozen and coronal sections (20μm in 
thickness) were cut with a Leica cryostat and floated them in PBS. The following 
protocol was used for immunofluorescence. The sections were washed 3-5min in PBS, 
and then preincubated in a blocking solution (10% normal bovine serum, 0.2% Triton 
X-100, 0.4% sodium azide in 0.01 mol/l PBS pH 7.2) for 30 min followed by 
incubation with the primary antibodies (P2X7 (1:1000), Alomone, rabbit polyclonal, 
APR-004; NeuN (1:500), Millipore, mouse monoclonal, clone A60; Iba-1 (1:500), 
Abcam, goat polyclonal, ab107159, biotin-conjugated IB4 (1:200), Sigma, L3019; 
GFAP (1:400), Boster (1:400), mouse monoclonal, BM0055) at room temperature 
overnight. Subsequently, the sections were incubated with Cy3-conjugated donkey 
anti-rabbit IgG (Jackson, 711-165-152) diluted 1:400 for P2X7, FITC-conjugated 
donkey anti-mouse IgG (Jackson, 705-475-151) 1:200 for NeuN and GFAP, 
FITC-conjugated donkey anti-goat IgG (Jackson, 715-475-003) 1:200 for Iba-1, 
Fluorescein-conjugated streptavidin (Jackson, 016-010-018) 1:200 for IB4. All 
incubations were separated by 5 -10 min washes in PBS.  
TUNEL Method and Double Labelling of TUNEL and 
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Immunohistochemistry  
In situ labeling of DNA fragmentation (terminal deoxynucleotidyl 
transferase-mediated UTP nick end labeling (TUNEL)) was carried out with an in situ 
cell death detection kit, Fluorescein (Roche, Mannheim, Germany, catalog number: 
11684795910) according to the manufacturer’s instructions. The apoptotic cells were 
labeled with green fluorescence.  
After detection of TUNEL, the sections were washed 3-5min in PBS, and then 
preincubated in a blocking solution for 30 min followed by incubation with the 
primary antibodies (NeuN (1:500), Millipore, mouse monoclonal, clone A60; Iba-1 
(1:500), Abcam, goat polyclonal, ab107159, mouse monoclonal GFAP (1:400), Boster, 
mouse monoclonal MBP (1:400), Boster and olig2, milipore, rabbit polyclonal, 
ab9610) at room temperature overnight. Subsequently, the sections were incubated 
with Cy3-conjugated donkey anti-rabbit IgG (Jackson, 711-165-152) diluted 1:400 for 
Olig2, Cy3-conjugated donkey anti-mouse IgG (Jackson, 715-165-150) 1:400 for 
NeuN and GFAP and Cy3-conjugated donkey anti-goat IgG (Jackson, 705-165-147) 
1:400 for Iba-1. All incubations were separated by 5 -10 min washes in PBS.  
Flow Cytometry   
Rats were anaesthetized by intraperitoneal injection with 4% chloral hydrate; 
cerebral spinal fluid (CSF) was sampled from the cisterna magna using a glass 
capillary and checked for the absence of blood contamination. CSF pooled from 3 rats 
was diluted with ice-cold phosphate-buffered saline (PBS) and subjected to 
differential centrifugation to obtain microvesicles at 16,000 g for 1 hour. The resulting 
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pellets were resuspended in 1x binding buffer and were then stained using the 
Annexin V-FITC/PI detection kit. The labelled samples were analyzed by flow 
cytometry (BD Biosciences, San Jose, CA, USA).  
Photomicroscopy  
 Images were taken with a Nikon digital camera DXM1200 (Nikon, Japan) 
attached to a Nikon Eclipse E600 microscope (Nikon). Images were imported into a 
graphics package (Adobe Photoshop 5.0, USA). 
 Western Blot 
For Western blotting, the rats were killed after 6h, 12h, 24h, 48h, 4d, 7d of TBI. 
The injured/adjacent cerebral cortexes and contralateral cortexes were removed 
immediately and lysed with 20 mM Tris–HCl buffer, pH8.0, containing 1% Nonidet P 
40, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.1% L-mercaptoethanol, 0.5 mM 
dithiothreitol, and a mixture of proteinase and phosphatase inhibitors (Sigma). Protein 
concentration was determined by the BCA protein assay method using bovine serum 
albumin (BSA) as standard. One hundred micrograms of protein samples was loaded 
per lane, separated by SDS-PAGE (10% polyacrylamide gels) and then was 
electrotransferred onto nitrocellulose membranes. The membranes were blocked with 
10% non-fat dry milk in Tris-buffered saline for 1 h and incubated overnight at 4 °C 
with P2X7 (1:1000, Alomone, rabbit polyclonal), p-p38(1:1000, CST, rabbit 
polyclonal), Tubulin (1:1000, Beyotime, mouse monoclonal) and GAPDH (1:1000, 
Beyotime, mouse monoclonal) diluted in 2% BSA in PBS. The membranes were then 
incubated with alkaline phosphatase–conjugated goat anti-rabbit IgG (Sigma) or goat 
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anti-mouse IgG (Sigma) diluted 1:5000 in 2% BSA in PBS for 1 h at room 
temperature. The colour development was performed with 400μg/ml nitro-blue 
tetrazolium, 200μg/ml 5-bromo-4-chloro-3-indolyl phosphate and 100 mg/ml 
levamisole in TSM2 (0.1 mol/l Tris–HCl buffer, pH 9.5, 0.1 mol/l NaCl and 0.05 
mol/l MgCl2) in the dark. Bands were scanned using a densitometer (GS-700; 
Bio-Rad Laboratories) 
ELISA for Tissue Il-1β levels  
Protein samples from the different groups of rats were collected as for the 
Western blot protocol described above. The samples were stored at -20°C until 
analyzed for IL-1β using the rat Il-1β ELISA kit from Multisciences. Assays were 
carried out according to the manufacturer’s instructions and the Optical Density (O.D.) 
was read at 450 nm using a Bio-Rad Model 680 Microplate Reader within 15 minutes. 
The standard curve was used to determine the amount of protein in the samples from 
the different groups of rats. Il-1β levels in the rat cerebral cortex tissue were 
expressed as picograms per milligram of protein sample.   
 Morris water maze 
At 8 days, spatial learning and memory were tested with the Morris water maze 
[18] which was a circular black tank of 130 cm in diameter and 60 cm in height. The 
tank was filled to a depth of 30 cm water at 25 ± 1°C. The maze was divided into four 
equal quadrants. The trials were performed according to Vorhees’ method [19]. 
Spatial acquisition: all rats received a training trial consisting of daily sessions of four 
consecutive trials for five days. The hidden platform (diameter 10 cm, 1.5 cm below 
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the water surface) was positioned in the middle of the southwest (SW) quadrant for all 
rats. The rats were released into the tank facing the maze wall at north (N), west (W), 
south (S), or east (E) quadrants in a predetermined pseudorandom order. A trial was 
terminated as soon as the rat found the platform; if the rat did not succeed within 120 
seconds, it was guided onto the platform with a stick. The rat was allowed to stay on 
the platform for 20 seconds before being removed. Probe trial: Immediately after the 
final training trial, the platform was removed. Rats were released into the pool at the 
NE position and allowed to swim freely for 2 minutes. The time needed to find the 
platform (escape latency) in the training trials and time spent in the SW quadrant in 
the probe trial were recorded. The mean value of four escape latencies in the daily 
four training trials was taken as the escape latency for the rat. Values from eight rats 
in the same group were averaged to generate a mean escape latency for that day.  
 Quantitative analysis  
Neuronal damage, apoptosis and MV-like particles were quantified by counting 
the number of surviving neurons, positive neurons for TUNEL and MV-like particles 
with P2X7-ir ( < 2.0μm) in the images at high magnification (×400) from the injured 
and adjacent regions. The numbers of surviving/TUNEL-positive neurons and total 
neurons in the regions were counted and analyzed by NIS-elements D3.1 system 
(Nikon, Japan). Ten sections were used for each rat and the mean number of these ten 
sections was calculated. Six rats were used for each experimental group.  
To quantify glial activation, we measured the value of the average area optical 
density (AAOD) for immunohistochemistry images from the injured region stained 
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with antibodies against GFAP using NIS-elements D3.1 system (Nikon, Japan). 
Pictures were taken using the same method as mentioned above. Ten images (200×) 
were randomly selected for each animal, and the mean AAOD of these ten fields was 
considered as the AAOD of the animal.  
Statistical analysis  
Results are expressed as mean ± SEM (n=5-6). Values were analyzed using a 
one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc test. p<0.05 
was considered to be statistically significant. 
Results 
The number of TBI-induced microglial MV-like particles in the cerebral cortex 
after TBI were reduced by a P2X7R antagonist and the immune modulator 
FTY720  
In the normal conditions, P2X7R immunoreactivity (P2X7R-ir) was detected 
only in the cells that were also labeled with Iba-1 (a microglial marker) antibody 
(Figure 1 A, D). This result implied that the P2X7R is predominately expressed in 
microglial cells in the cerebral cortex of adult rats. After TBI, the microglial cells with 
P2X7R-ir transformed into amoeboid-like cells in the injured and adjacent regions. 
There were numerous MV-like particles with P2X7R-ir around the amoeboid cells, 
the number of these particles reached a peak at 12 hours after TBI and disappeared 
after 48 hours (Figure 1 B, C, G, H, Figure 2A). The number of amoeboid-like cells 
with P2X7R-ir increased 48 hours after TBI (Figure 1, 2). A804598 and FTY720 
inhibited significantly the number of MV-like particles and amoeboid-like cells with 
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P2X7R-ir (Figure 1E-L, Figure 2B). In order to analyze the source of the MV-like 
particles, a double immunofluorescence technique was carried out. The results 
showed that almost all the MV-like particles were also labeled with Iba-1, but not with 
GFAP or MBP (Figure 3). The results confirmed that these MV-like particles 
predominately originated from microglial cells.  
CSF samples were collected from TBI, TBI+A804598 and TBI+FTY720 group 
rats, and analyzed by flow cytometry. The results showed that the number of particles 
with Annexin V-FITC reached a peak value 12 hours after TBI. A804598 and 
FTY720 inhibited significantly the number of particles with Annexin V-FITC (Figure 
4). The particles were further analyzed by immunocytochemistry. The results showed 
that 85% of the particles were both P2X7R-ir and Iba1-ir (Figure 4F), which implies 
that most of the particles in the CSF samples originated from microglial cells.  
Western blot analysis showed that expression of P2X7R protein in the injured 
areas and adjacent cerebral cortex increased gradually after TBI (Fig. 5). A804598 
and FTY720 did not inhibit P2X7R protein expression significantly, as shown in 
Figure 5. The molecular weight of the three bands with P2X7R-ir were located around 
72kd. The bands disappeared after the antibody was preincubated with the control 
peptide antigen (supplementary Figure 1).  
 
The number of apoptotic cells was reduced and the number of neurons that 
survived was increased in the cerebral cortex after TBI by use of a P2X7R 
antagonist and the immune modulator FTY720 
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Apoptotic cells were studied using the TUNEL technique. The results showed 
that many apoptotic cells were detected from 6 hour to 48 hours after TBI. A804598 
and FTY720 decreased significantly the number of the apoptotic cells, as shown in 
Figure 6. The double labeling technique of TUNEL and immunohistochemistry 
showed that most of the apoptotic cells were NeuN positive, occasionally Iba-1 or 
GFAP positive, but never Olig2 positive (Figure 7). The result indicates that most of 
the apoptotic cells are neurons after TBI.  
The neurons that survived were studied by NeuN immunostaining. The results 
showed that the number of NeuN-positive neurons decrease significantly in the TBI 
group, compared to the control group. Both A804598 and FTY720 increased the 
survival of neurons in the injured and adjacent regions (Figure 8). These results show 
that A804598 and FTY720 have neuroprotective roles after TBI.  
P2X7R or FTY720 mediates IL-1β expression after TBI  
IL-1β expression was detected at a low level in the sham rat cerebral cortex. 
After TBI, the level of expression of IL-1β increased. 48 h after TBI, the level of 
expression of IL1β reached a peak. Treatment with A804598 or FTY720 significantly 
reduced the expression of IL-1β within the cerebral cortex, as assessed by ELISA 
(Figure 9).  
The p38 signaling pathway has been shown to be involved in MV shedding and 
IL-1β secretion from microglia. Phosphorylated p38 was detected in the sham rat 
cerebral cortex at a low level. After TBI, the level of phosphorylated p38 increased. 
At 12 h after TBI, the level of phosphorylated p38 reached a peak (Figure 10). 
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Treatment with A804598 or FTY720 significantly reduced the level of 
phosphorylated p38 at 12 h and 24 h, as assessed by Western blotting (Figure 10).  
Inhibition of the P2X7R FTY720 reduces TBI-induced glial activation 
Reactive astrogliosis was assessed by immunohistochemical analysis of the 
expression of GFAP (an astrocyte marker) in the injured and adjacent regions of 
cerebral cortex at 12 hours, 2 days, 4 days, 7 days and 14 days after TBI. The 
scattered GFAP-ir cells with thin and long processes were detected in the cerebral 
cortex region of the sham rat. However, both the immunostaining density and the 
number of GFAP-ir cells significantly increased in the saline group. Treatment with 
A804598 or FTY720 markedly attenuated the increase of immunostaining density and 
the number of GFAP-ir cells when compared to the saline group (Figure 11).  
Inhibition of the P2X7R or FTY720 improves neurobehavioral outcomes after 
TBI   
Spatial memory was evaluated using the Morris water maze. During the 5-day 
hidden platform trial, escape latency of sham and the three experimental groups 
decreased in a day-dependent pattern. However, the sham group took significantly 
less time to find the platform than the saline group on all five days. In addition, the 
saline group required significantly more time to find the platform than the A804598 
and FTY720 groups after the ninth day. In the probe trial, the saline group spent 
significantly less time than the other three groups in the SW quadrant. There was no 
significant difference among the sham, A804598 and FTY720 groups (Figure 12).     
 
Discussion  
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The main finding of this study is that the P2X7R antagonist A804598 and the 
immune modulator FTY720 reduced neuron apoptotic cell death and increased the 
survival of neurons in the injured cerebral cortex injured and adjacent regions after 
TBI. P2X7R expression was up-regulated on microglial cells after TBI. Inhibition of 
the P2X7R and FTY720 reduced TBI-induced microglial MV-like particles, IL-1β 
expression, P38 phosphorylation, glial activation in the cerebral cortex, and improved 
neurobehavioral outcomes after TBI.   
ATP is an important signaling molecule mediating interactions among various 
cell types in the brain [10, 11,12, 20-26]. A low level of extracellular ATP is 
maintained in physiological conditions [25, 27], with the cytoplasmic ATP 
concentration is in the millimolar range. Activated immune cells [28], macrophages 
[29], microglia [30], astrocytes [31], platelets [32], and dying cells [33] may release 
high concentrations of ATP into the extracellular space. Massive release of ATP also 
occurs after metabolic stress and trauma, and high levels of ATP persist in the injured 
zone for an extended time [8, 20, 34-36]. ATP is not rapidly degraded during 
inflammation or oxidative stress conditions, as the enzymes for extracellular ATP 
degradation are inhibited [37].  
The receptors for extracellular ATP are termed P2 receptors, which have been 
divided into P2X and P2Y receptors on the basis of pharmacology and molecular 
cloning. Currently, seven subtypes of ionotropic P2X receptors (non-selective cation 
channels) and eight subtypes of metabotropic P2Y receptors (G protein-coupled 
receptors) have been characterised [38, 39]. The P2X7R is predominantly expressed 
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on microglia and ependyma of the CNS [40, 41]. P2X7R can be activated by high 
concentrations of ATP. Sustained stimulation of P2X7R on microglia leads to the 
activation of microglia, which produces reactive oxygen species and 
pro-inflammatory cytokines and is involved in neuroinflammation in many CNS 
diseases including, Alzheimer’s disease [42], epilepsy [43], spinal cord injury [8, 44], 
multiple sclerosis (MS) [45] and traumatic brain injury [58].  
Our previous data and other researchers have shown that high concentrations of 
extracellular ATP can stimulate microglial cells or macrophages to shed MVs [46, 47, 
48]. MVs belong to the group of extracellular vesicles (EVs). Increasing evidence has 
shown that EVs play important roles in intercellular communications by serving as 
vehicles for transfer between cells of membrane and cytosolic proteins, lipids, and 
RNA. Those originating from endosomal membrane are called exosomes, and those 
originating from plasma membrane are called MVs [49].  
The present data has shown that MV-like particles from the microglial cells were 
mainly detected during a short time period of 6-12h, and dramatically decreased at 24 
hours, disappearing from 48h after TBI. The appearance and disappearance of these 
MV-like particles were accompanied by morphological changes of the microglial cells, 
as they ramified to amoeboid microglia. These data imply that MV-like particles are 
released during the processes of microglial morphological change. Increasing data has 
shown that purinoceptors are involved in the morphological changes of microglia [21, 
50, 27] and MV shedding [13, 46, 47, 48]. Persistent high ATP release was also 
detected in the peritraumatic region during the early stage of 2-6 hours and returned to 
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the background level 24 hours after spinal cord injury [8]. The time course of the ATP 
concentration change was similar to that of shedding of the MV-like particles detected 
in this study. Thus, high ATP release might be expected to be evident during the early 
stages, 6-12 hours after TBI. These high concentrations of ATP may be involved in 
the MV-like particle shedding and morphological changes of microglial cells, 
although further experiments are needed to answer this issue. 
Increasing evidence has shown that MVs discharged by activated microglia act 
as amplifying agents of inflammation and has identified MVs as a marker and 
therapeutic target of brain inflammation [13]. P2X7R-induced MV shedding acts as a 
secretory pathway for rapid release of IL-1β and may represent a general mechanism 
for secretion of leaderless secretory proteins from P2X7R-expressing myeloid cells 
[13, 46, 51] . P2X7R, P38 MAPK and A-SMase play key roles in MV shedding from 
microglia [13].  
A report showed that mice, where microglia were p38-deficient (p38 KO), were 
protected against TBI-induced motor deficits and synaptic protein loss. In wild-type 
(WT) mice, TBI produced microglia morphological activation that lasted for at least 7 
days; however, p38 KO mice failed to activate this response. The results showed that 
the p38 signaling pathway in microglia could be contributing to the secondary 
neuroinjury after TBI [52]. In this study, we also showed that phosphorylation levels 
of P38 protein increased after TBI. Both A804598 and FTY720 decreased this level. 
This result further confirmed that the P38 pathway plays a role in secondary 
neuroinjury after TBI 
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     FTY720 (Gilenya) is an analog of the naturally occurring myriocin. The 
therapeutic action of FTY720 in MS is to inhibit the exit of autoreactive memory 
T-cells from secondary lymphoid organs to produce a peripheral lymphopenia [53]. 
FTY720 has been marketed as the first oral sphingosine-1-phosphate receptor 
modulator for the treatment of MS, but it also inhibits lysosomal A-SMase [16].  
The present data has shown that both A804598 and FTY720 significantly 
decreased the number of MV-like particles in the injured/adjacent cerebral cortex 
regions and CSF after TBI and improved the outcomes of neuronal survival, gliosis 
and neurobehaviour after TBI. These data imply that A804598 and FTY720 could be 
used as drugs for treatment of secondary neuronal injury after TBI, as they target 
P2X7R and A-SMase, respectively. We believe that P2X7R and A-SMase could be 
used as new therapeutic targets for TBI.  
Astrogliosis is the hypertrophy and increase in number of astrocytes due to the 
destruction of nearby neurons from different pathological causes, which alters 
astrocyte activities, both through gain and loss of functions that can impact both 
beneficially and detrimentally on surrounding neural and non-neural cells [54, 55].  
Astrogliosis is a ubiquitous but poorly understood hallmark of all CNS 
pathologies [55]. Many different molecules are found to be able to trigger reactive 
astrogliosis processes. These astrogliosis molecular mediators can be released by any 
cell type in the CNS. These mediator molecules include cytokines and growth factors, 
mediators of innate immunity, neurotransmitters and modulators, small molecules 
released following cell injury, molecules of oxidative stress, and systemic metabolic 
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toxicity. These molecules, via different signaling routes, trigger different molecular, 
morphological and functional changes in reactive astrocytes [55].  
IL-1 is an astrogliosis molecular mediator [56, 57]. IL-1β induces IL-6 release, 
which further induces astrogliosis [57 Woiciechowsky et al, 2004]. In this study, the 
data showed that IL-1β increased after TBI, which was partially blocked by both the 
P2X7R antagonist, A804598, and the immune modulator, FTY720. Astrogliosis was 
also partially inhibited by these two drugs.  
In summary, the techniques of immunohistochemistry, TUNEL, Western blotting, 
flow cytometry, ELISA, and neurobehavioural tests used in his study have shown that 
the P2X7R antagonist A804598 and the immune modulator FTY720 reduced neuron 
apoptotic cell death and increased the survival of neurons in the injured cerebral 
cortex and adjacent regions after TBI. A possible mechanism is that high 
concentrations of extracellular ATP after TBI, via P2X7R, activates microglial cells, 
which discharge MV-like particles involving local neuroinflammation. Inhibition of 
the P2X7R and A-SMase reduced TBI-induced microglial MV-like particles, IL-1β 
expression, P38 phosphorylation, glial activation in the cerebral cortex, and improved 
neurobehavioral outcomes after TBI.   
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Figure Legends 
Figure 1. Expression of P2X7R-ir (red) in the cerebral cortex of control and TBI rats. 
A is P2X7R-ir, D is an immerged image from A (red) and Iba-1-ir (green, a marker for 
microglial cell) from the control group. Note that almost all the P2X7-ir are also 
labeled with Iba-1. The immunstaining results show that P2X7R-ir is predominately 
expressed in microglial cells. B, C, G, H, and I are P2X7R-ir from the TBI groups at 
6h, 12h, 24h, 48h and 72h, respectively. E, J, L, F, and L are P2X7R-ir from 
TBI+A804598 and TBI+FTY720 groups. Note that microvesicle (MV)-like particles 
were detected mainly at 6h and 12h after TBI, and A804598 and FTY720 decreased 
significantly the number of vesicles. In the early stages from 6h to 24h after TBI, the 
number of P2X7R-ir microglial cells did not change significantly, but increased from 
48h after TBI. Both A804598 and FTY720 decreased the number of microglia cells 
significantly at 96 h after TBI. All scale bars = 60µm.  
 
Figure 2. Quantitative analysis of MV-like particles (A) and microglial cells (B) with 
P2X7R-ir after TBI. The number of MV-like particles and microglial cells is 
expressed as mean ± S.E.M. (n=6). Note that MV-like particles were mainly detected 
at 6h and 12h after TBI; both A804598 and FTY720 reduced significantly the number 
of MV-like particles at 6h and 12h and the number of microglial cells at 96h.  
**p<0.01.  
 
Figure 3. Double immunofluorescence of P2X7R-ir (red), Iba-1 (green), GFAP (green) 
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and MBP (green) in the cerebral cortex of rats 12h after TBI. A, C and E are P2X7R-ir. 
B, D and F are the merged images of Iba-1-ir, GFAP-ir and MBP-ir with A, C and E, 
respectively. b is a magnified image of the region of B indicated by an arrow. Note 
that almost all the MV-like particles and cells with P2X7-ir are also labeled with 
Iba-1-ir, but not with GFAP-ir or MBP-ir. The scale bars in A-F= 60µm, b=10µm.  
 
Figure 4. Flow cytometry and immunocytochemical analysis of MV-like particles in 
CSF after TBI. A, B, C and D show the results from control, TBI, TBI+A804598, and 
TBI+FTY720 groups at 12 h after TBI. E shows the summary of flow cytometry of 
CSF from different groups. Note that the number of MV-like particles reaches a peak 
at 12h. Both A804598 and FTY720 significantly reduced the number of MV-like 
particles at 6h and 12h. F is immunocytochemical analysis of MV-like particles with 
P2X7R (red) and Iba-1 immunostaining (green). Note that most of MV-like particles 
with P2X7R-ir are also labelled by Iba-1, although some of them are not. An arrow 
indicates an MV-like particle with Iba-1, not labelled by P2X7R-ir (shown at higher 
magnification in f).  
 
Figure 5. Expression of P2X7R detected by Western blotting in the cerebral cortex 
from TBI (A), TBI+A804598 (B) and TBI+FTY720 (C) groups. D is the summary of 
P2X7R/GAPDH ratio. Data are representative of 5 rats per group. The ratio of 
P2X7R/GAPDH was analyzed with one-way ANOVA followed by Dunnett’s post hoc 
test (**p<0.01 vs. control sham operated rats). The results show that expression of 
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P2X7R protein increased significantly from 6h to 7d after TBI, but was not affected 
by A804598 or FTY720.  
 
Figure 6. Effect of A804598 and FTY720 on cell apoptosis in the cerebral cortex after 
TBI. A, C, E, G, I and K are TUNEL staining from the control, 6h, 12h, 24h, 48h, and 
96h groups, respectively. D, H, L, F, and J are TUNEL staining from TBI+A804598 
and TBI+FTY720. M is the summary of the number of TUNEL-positive cells in the 
different groups. Note that A804598 or FTY720 treatment significantly reduced the 
number of apoptotic cells. Values are expressed as the mean ± S.E.M. **p<0.01 
TBI+A804598 groups or TBI+FTY720 groups versus saline-treated groups. All the 
scale bars=60μm.  
 
Figure 7. Cell type analysis of apoptotic cells in the cerebral cortex at 6 h after TBI. A, 
D, G, and J show TUNEL-positive cells, B, E, H, and K show NeuN-positive, 
GFAP-positive, Iba-1-positive and Olig2-positive cells in the same fields of A, D, G, 
and J, respectively. C, F, I, and L show immerged images from A and B, D and E, G 
and H, and J and K. Note that most of the apoptotic cells were NeuN positive, 
occasionally Iba-1 or GFAP positive, but never Olig2 positive. The results indicate 
that most of the apoptotic cells after TBI are neurons. All scale bars = 60μm.  
 
Figure 8. Fig. 2 Effect of A804598 and FTY720 on neuronal survival rate in the 
cerebral cortex after TBI. A, B, C, and D are NeuN immunostaining from the control 
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group, TBI group, TBI+A804598 group, and TBI+FTY720 group 14 days after TBI, 
respectively. E summarizes the number of survival neurons. Note that both A804598 
and FTY720 treatment increased significantly the number of surviving neurons. 
Values are expressed as mean ± S.E.M. *p<0.05, **p<0.01. 2w (2weeks) =14 days. 
All scale bars= 60μm.  
 
Figure 9. Effect of A804598 and FTY720 on expression of interleukin (IL)-1β in the 
cerebral cortex after TBI. IL-1β protein was detected by ELISA. Both A804598 
FTY720 reduced significantly the levels of IL-1β. Data are expressed as mean ± 
S.E.M. *p<0.05, **p<0.01.   
 
Figure 10. Expression of phosphorylation P38 (pP38) detected by Western blotting in 
the cerebral cortex from TBI (A), TBI+A804598 (B) and TBI+FTY720 (C) groups. D 
is the summary of pP38/Actin ratio. Data are representative of 5 rats per group. The 
ratio of pP38/Actin was analyzed with one-way ANOVA followed by Dunnett’s post 
hoc test (**p<0.01 TBI vs. TBI+A804598 or TBI+FTY720 rats). Statistical analysis 
shows that pP38 protein increased significantly at 12h and 24h after TBI, which was 
inhibited by A804598 or FTY720, significantly.  
 
Figure 11. Effect of A804598 and FTY720 on astrogliosis in the cerebral cortex after 
TBI. A-F show astrocytes with GFAP-ir at 4d, 7d (1w), and 14d (2w) in the 
TBI+saline groups (A, B, C), TBI+A804598 groups (D, F), TBI+FTY720 group (E) 
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respectively. G shows the quantitative analysis of average area optical density 
(AAOD) of astrocytes with GFAP-ir. Data are expressed as mean ± S.E.M (n=6). 
**p<0.01. Statistical analysis shows that density of GFAP-ir increased gradually after 
TBI. A804598 or FTY720 reduced the density of GFAP-ir significantly at 7d and 14d 
after TBI.  
 
Figure 12. Effect of A804598 and FTY720 on spatial learning and memory in the 
water maze. A shows escape latency to find the platform during the 5 days of the 
training trial from the 8th to the 12th day after TBI. B shows time spent during the 
probe trial in the quadrant where the platform had been located. Values are expressed 
as mean ± S.E.M. **p<0.01, *p<0.05. Statistical analysis shows that spatial learning 
and memory were effected significantly by TBI. Both A804598 and FTY720 
improved spatial learning and memory after TBI.  
 
